🔎︎
French sailor Charlie Dalin completed a 24,000-mile solo journey around the world while receiving daily immunotherapy for gastrointestinal cancer, demonstrating the potential for cancer patients to maintain demanding physical activities under carefully monitored medical supervision. The Washington Post reported that Dalin won the Vendée Globe race in January 2025 in a record 64 days while managing his diagnosis, which was made in fall 2023 when a 15-centimeter gastrointestinal stromal tumor was discovered.
The 41-year-old sailor worked closely with oncologist Axel Le Cesne and race physician Laure Jacolot to determine whether competing was medically feasible. Scans performed days before the race showed the tumor had not grown during his immunotherapy treatment. Throughout the voyage, Dalin maintained a strict medication schedule with daily alarms and modified his sleep patterns to average six and a half hours per day, significantly more than typical solo racers require.
The decision to compete involved complex risk-benefit considerations. Jacolot noted that medicine cannot definitively determine whether the race prolonged or shortened the patient's life, acknowledging the uncertainty inherent in managing cancer treatment alongside extreme physical demands. Dalin completed the race maintaining therapeutic drug levels while navigating severe weather conditions and managing intermittent abdominal pain.
Following his victory, Dalin underwent surgery six weeks later to remove a portion of his intestine. The disease progressed in spring 2025, requiring additional treatments. He has since placed his sailing career on hold while continuing therapy, though he remains optimistic about potentially returning to less demanding transatlantic races in the future.
The case illustrates how precision oncology approaches and targeted therapies may allow select patients to pursue physically demanding activities when disease remains stable and patients maintain strict adherence to treatment protocols under close medical supervision.
